Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans

Background Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) may positively or negatively impact outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We investigated the association of ARB or ACEI use with coronavirus disease 2019 (COVID-19)-related outcomes in US Veterans with treated hypertension using an active comparator design, appropriate covariate adjustment, and negative control analyses. Methods and findings In this retrospective cohort study of Veterans with treated hypertension in the Veterans Health Administration (01/19/2020-08/28/2020), we compared users of (A) ARB/ACEI vs. non-ARB/ACEI (excluding Veterans with compelling indications to reduce confounding by indication) and (B) ARB vs. ACEI among (1) SARS-CoV-2+ outpatients and (2) COVID-19 hospitalized inpatients. The primary outcome was all-cause hospitalization or mortality (outpatients) and all-cause mortality (inpatients). We estimated hazard ratios (HR) using propensity score-weighted Cox regression. Baseline characteristics were well-balanced between exposure groups after weighting. Among outpatients, there were 5.0 and 6.0 primary outcomes per 100 person-months for ARB/ACEI (n = 2,482) vs. non-ARB/ACEI (n = 2,487) users (HR 0.85, 95% confidence interval [CI] 0.73–0.99, median follow-up 87 days). Among outpatients who were ARB (n = 4,877) vs. ACEI (n = 8,704) users, there were 13.2 and 14.8 primary outcomes per 100 person-months (HR 0.91, 95%CI 0.86–0.97, median follow-up 85 days). Among inpatients who were ARB/ACEI (n = 210) vs. non-ARB/ACEI (n = 275) users, there were 3.4 and 2.0 all-cause deaths per 100 person months (HR 1.25, 95%CI 0.30–5.13, median follow-up 30 days). Among inpatients, ARB (n = 1,164) and ACEI (n = 2,014) users had 21.0 vs. 17.7 all-cause deaths, per 100 person-months (HR 1.13, 95%CI 0.93–1.38, median follow-up 30 days). Conclusions This observational analysis supports continued ARB or ACEI use for patients already using these medications before SARS-CoV-2 infection. The novel beneficial association observed among outpatients between users of ARBs vs. ACEIs on hospitalization or mortality should be confirmed with randomized trials.

[1]  C. Granger,et al.  Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[2]  T. Chang,et al.  Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial , 2021, The Lancet Respiratory Medicine.

[3]  D. Kansagara,et al.  Update Alert 7: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults , 2021, Annals of Internal Medicine.

[4]  A. Harky,et al.  The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients , 2021, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[5]  J. Rigdon,et al.  Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during coronavirus disease 2019: beyond confounding. , 2020, Journal of hypertension.

[6]  Angelica M. Walker,et al.  A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm , 2020, eLife.

[7]  Jordana B. Cohen,et al.  Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System , 2020, Advances in Chronic Kidney Disease.

[8]  D. Batlle,et al.  Kidney and Lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: implications for COVID-19 , 2020, bioRxiv.

[9]  D. Diz,et al.  COVID-19, ACE2, and the cardiovascular consequences , 2020, American journal of physiology. Heart and circulatory physiology.

[10]  L. Tomlinson,et al.  Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[11]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[12]  Corrigendum to: 2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[13]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[14]  Jackson T. Wright,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American Society of Hypertension : JASH.

[15]  J. Williamson,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Hypertension.

[16]  A. Althouse.  Adjust for Multiple Comparisons? It's Not That Simple. , 2016, The Annals of thoracic surgery.

[17]  David B Richardson,et al.  The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application , 2015, Current Epidemiology Reports.

[18]  M. Fox,et al.  Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors , 2015, Amino Acids.

[19]  Jeremy A Rassen,et al.  Metrics for covariate balance in cohort studies of causal effects , 2014, Statistics in medicine.

[20]  Liang Li,et al.  A Weighting Analogue to Pair Matching in Propensity Score Analysis , 2013, The international journal of biostatistics.

[21]  L. Burrell,et al.  Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. , 2012, Clinical science.

[22]  Chen Yu,et al.  Counteraction between angiotensin II and angiotensin-(1–7) via activating angiotensin type I and Mas receptor on rat renal mesangial cells , 2012, Regulatory Peptides.

[23]  Kenji Suzuki,et al.  Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1–7 mas receptor , 2012, Free radical research.

[24]  Yan Leng,et al.  Angiotensin II AT1 Receptor Blockade Ameliorates Brain Inflammation , 2011, Neuropsychopharmacology.

[25]  M. Tonelli,et al.  Validation of a case definition to define chronic dialysis using outpatient administrative data , 2011, BMC medical research methodology.

[26]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[27]  J. Penninger,et al.  Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression , 2011, Regulatory Peptides.

[28]  Hude Quan,et al.  Validation of a Case Definition to Define Hypertension Using Administrative Data , 2009, Hypertension.

[29]  J. Saavedra,et al.  In vivo Angiotensin II AT1 receptor blockade selectively inhibits LPS-induced innate immune response and ACTH release in rat pituitary gland , 2009, Brain, Behavior, and Immunity.

[30]  L. Burrell,et al.  Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition , 2009, Clinical science.

[31]  D. Batlle,et al.  Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. , 2009, American journal of physiology. Renal physiology.

[32]  F. van Lente,et al.  Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. , 2008, Journal of the American College of Cardiology.

[33]  H. van Goor,et al.  Differential regulation of renal angiotensin‐converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats , 2008, Experimental physiology.

[34]  D. Averill,et al.  Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. , 2005, Kidney international.

[35]  H. Quan,et al.  Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.

[36]  D. Diz,et al.  Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2 , 2005, Circulation.

[37]  N. Hooper,et al.  Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. , 2004, The Biochemical journal.

[38]  D. Averill,et al.  Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II Receptors , 2004, Hypertension.

[39]  R. Feise.  Do multiple outcome measures require p-value adjustment? , 2002, BMC medical research methodology.

[40]  O. Carretero,et al.  Vasodilator Action of Angiotensin-(1-7) on Isolated Rabbit Afferent Arterioles , 2002, Hypertension.

[41]  J W DiLeonardi,et al.  Using administrative data. , 2000, Child welfare.

[42]  M. Romero,et al.  Modulation of phospholipase A2 activity and sodium transport by angiotensin-(1-7). , 1993, Kidney international.

[43]  D B Rubin,et al.  Multiple imputation in health-care databases: an overview and some applications. , 1991, Statistics in medicine.

[44]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.

[45]  D. Rubin,et al.  Reducing Bias in Observational Studies Using Subclassification on the Propensity Score , 1984 .

[46]  J. Luban.  SARS-CoV-2 , 2020 .